Last year, Brooks had entered into a collaboration with SteriScience to carry out manufacturing, marketing and distribution of carbapenems for the global markets with an integrated infrastructure to manufacture both drug substances and drug products. As part of this collaboration, Brooks and SteriScience had setup BSL, a joint venture company engaged in the manufacturing of the carbapenem products which also housed the manufacturing facility at Vadodara, India.
SteriScience has already invested Rs. 40 crore into BSL, and as per the new agreement signed, SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL.
The new investments will be deployed to set up a dedicated Ertapenem formulation facility and integrate the APIs for all the four carbapenems under development. Besides this, BSL will also set up front-end capabilities to market carbapenem products globally, including the US, Europe, Canada, Australia and India. BSL has already filed its first ANDA in addition to dossier submissions for 30+ European countries. Going forward Brooks Steriscience (the current manufacturing JV) will be the only effective JV and SteriBrooks Penems (the Marketing JV), will be merged or dissolved as per legal advice in due course. All IPs / ANDAs / Dassiers will be owned by BSL across the world.
After completing new investments of Rs. 74.5 crore, SteriScience will have 51% of BSL, while Brooks will have the remaining 49% ownership.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
